Home   About this service   Get the news  
+32 2 743 34 03

UCB [BE0003739530 / UCB]

UCB Media Room: Acquisitions and disposals of own shares


[02/04/2021 | 20:04]

** Acquisitions of own shares and disposals of own shares

Brussels (Belgium), 2 April 2021 =E2=80=93 20:00 (CEST) =E2=80=93 regulated=

Acquisitions of own shares

In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi=
ng the Belgian Code on Companies and Associations, UCB SA/NV (=E2=80=9CUCB=
=E2=80=9D or the =E2=80=9CCompany) (Euronext Brussels: UCB) hereby disclose=
s certain information in relation to its Share Repurchase Program 2021.=C2=

Under this program, UCB has requested a financial intermediary to repurchas=
e up to 750 000 UCB shares on its behalf under the terms of an initial disc=
retionary mandate agreement with validity until 25 June 2021, effective as =
from 8 March 2021, to cover current and future obligations under UCB's Long=
Term Incentive Plans for its personnel.

In the framework of this Share Repurchase Program 2021, UCB repurchased 76 =
373 UCB shares on Euronext Brussels in the period from 26 March 2021 up to =
and including 1st April 2021, as follows:=C2=A0


Disposal of own shares

In accordance with article 8:6 of the Royal Decree executing the Belgian Co=
de of Companies and Associations, UCB announces that, following exercises o=
f stock options by members of its personnel, it has disposed of UCB shares =
OTC in view of deliveries of these shares to the relevant members of the pe=
rsonnel, within the framework of the Long Term Incentive Program of the UCB=
Group, as follows:

In addition to these exercises, on 1 April 2021, in accordance with the ves=
ting rules under its 2018 LTI plans, UCB SA/NV has delivered for free a tot=
al of 408 810 UCB shares OTC to 1 439 members of the personnel of the Compa=
ny and its subsidiaries. The highest independent bid price on Euronext Brus=
sels on 1 April 2021 was =E2=82=AC 81.60.

This press release is available on UCB SA/NV=E2=80=99s website via the foll=
owing link (https://www.ucb.com/stories-media/Press-Releases) .

Investor Relations
Antje Witte =C2=A0 =C2=A0 =C2=A0 =C2=A0 =C2=A0
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck,
=C2=A0Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com=C2=A0
=C2=A0=C2=A0 =C2=A0
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 8 400 peopl=
e in nearly 40 countries, the company generated revenue of =E2=82=AC 5.3 bi=
llion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us =
on Twitter: @UCB_news

210402 - UCB Acquisitions and disposals of own shares ENG final (https://mb=
.cision.com/Public/18595/3319421/a202e7b56c7eaabd.pdf) GenericFile
210402- Verwerving en vervreemding van eigen aandelen NED (https://mb.cisio=
n.com/Public/18595/3319421/a713559b83d75513.pdf) GenericFile
210402- Rachat et ali=C3=A9nation d actions propres FR (https://mb.cision.c=
om/Public/18595/3319421/9d05f63bb7b4af74.pdf) Image
Capture 1 April 2 2021 (https://mb.cision.com/Public/18595/3319421/a27df9a6=
fe54b17e_org.png) Image
Capture 2 April 2 2021 (https://mb.cision.com/Public/18595/3319421/92bf5aa9=
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x65665x1x6868579x24000=
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=